Acting On Ester Bond (3.1) Patents (Class 435/196)
-
Patent number: 8871485Abstract: Disclosed herein are modified carbonic anhydrase enzymes, and a process of using same for the extraction, production and purification of carbon dioxide gas. More particularly, modified carbonic anhydrase enzymes are used for the production, purification of carbon dioxide and the products of the hydration reaction, hydrogen and bicarbonate ions Also, this technology is used to enhance the production of carbon dioxide in blood or in reverse osmosis desalination to remove carbon dioxide. Specifically, the invention relates to a modified carbonic anhydrase enzyme possessing improved activity and a process whereby immobilized modified carbonic anhydrase contained within a reactor device catalyzes the reversible hydration of carbon dioxide.Type: GrantFiled: June 22, 2011Date of Patent: October 28, 2014Assignee: University of Florida Research Foundation, Inc.Inventors: Robert McKenna, David N. Silverman
-
Publication number: 20140314735Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.Type: ApplicationFiled: July 1, 2014Publication date: October 23, 2014Inventor: Stefan NILSSON
-
Publication number: 20140315313Abstract: Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications.Type: ApplicationFiled: April 20, 2012Publication date: October 23, 2014Applicant: DANISCO US INC.Inventors: Elizabeth A. Bodie, Robert James Pratt, II
-
Patent number: 8865407Abstract: This document provides methods and materials for detecting target nucleic acid. For example, methods and materials for detecting the presence or absence of target nucleic acid, methods and materials for detecting the amount of target nucleic acid present within a sample, kits for detecting the presence or absence of target nucleic acid, kits for detecting the amount of target nucleic acid present within a sample, and methods for making such kits are provided.Type: GrantFiled: December 19, 2013Date of Patent: October 21, 2014Assignee: Cascade Biosystems, Inc.Inventors: Kenneth D. Smith, Nina Yazvenko, Mariya Smit
-
Publication number: 20140308701Abstract: The present invention relates to recombinant filamentous fungal host cells producing cellulolytic enzyme compositions and methods of producing and using the compositions.Type: ApplicationFiled: August 23, 2012Publication date: October 16, 2014Inventors: Jeffrey Shasky, Amanda Fischer, Suchindra Maiyuran
-
Patent number: 8859252Abstract: The present invention relates generally to prostatic acid phosphatase (PAP), compositions comprising the same, and methods for producing and/or purifying the same.Type: GrantFiled: January 2, 2014Date of Patent: October 14, 2014Assignee: Aerial BioPharma, LLCInventors: Jonathan Mitschelen, John Lightholder, Gary Bream, Kenneth Freeman
-
Publication number: 20140294822Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.Type: ApplicationFiled: February 28, 2014Publication date: October 2, 2014Applicant: ARMAGEN TECHNOLOGIES, INC.Inventors: William M. PARDRIDGE, Ruben J. BOADO
-
Publication number: 20140298505Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.Type: ApplicationFiled: June 6, 2012Publication date: October 2, 2014Inventor: Ralf Kühn
-
Publication number: 20140295493Abstract: The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Inventors: Hiroaki Udagawa, Christian Isak Jorgensen
-
Publication number: 20140295457Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.Type: ApplicationFiled: October 11, 2012Publication date: October 2, 2014Inventors: Mark Broenstrup, Claudia Koenig, Luigi Toti, Joachim Wink, Wulf Leuschner, Johann Gassenhuber, Rolf Müller, Silke Wenzel, Tina Binz, Carsten Volz
-
Publication number: 20140294773Abstract: A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression.Type: ApplicationFiled: December 21, 2012Publication date: October 2, 2014Inventors: Stan Johan Jozef Brouns, John Van Der Oost
-
Patent number: 8846887Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.Type: GrantFiled: May 24, 2012Date of Patent: September 30, 2014Assignee: University of Kentucky Research FoundationInventors: Chang-Guo Zhan, Fang Zheng, Wenchao Yang
-
Patent number: 8846363Abstract: This invention is related, in part, to sulfatase enzymes and methods of their use.Type: GrantFiled: October 22, 2010Date of Patent: September 30, 2014Inventors: James R. Myette, Ram Sasisekharan
-
Publication number: 20140283819Abstract: The present invention relates to plant cells and plants that are genetically modified, whereby the genetic modification leads to a decrease in the activity of a starch dephosphorylating LSF-2 protein in comparison to corresponding wild type plant cells or wild type plants that have not been genetically modified. The present invention also relates to means and methods for the manufacture of such plant cells and plants. These types of plant cells and plants synthesise a modified starch. Therefore, the present invention also concerns the starch synthesised from the plant cells and plants according to the invention, methods for the manufacture of this starch, and the manufacture of starch derivatives of this modified starch, as well as flours containing starches according to the invention. In addition, the present invention relates to chimeric genes comprising nucleic acids encoding a starch dephosphorylating LSF-2 protein, vectors, host cells such as plant cells, and plants containing such chimeric genes.Type: ApplicationFiled: October 10, 2012Publication date: September 25, 2014Inventors: Samuel C. Zeeman, Oliver Koetting, Diana Santelia
-
Publication number: 20140273231Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: ApplicationFiled: April 23, 2014Publication date: September 18, 2014Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Feng ZHANG, Le CONG
-
Publication number: 20140273226Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification and regulation of gene expression in mammalian cells. The specification describes the design and validation of polynucleotides encoding the Streptococcus pyogenes (S. pyogenes) Cas9 gene and protein and variants of that protein, where the nucleotide sequence has been optimized for expression in mammalian cells, and also modified by fused sequences that enhance various aspects of the CRISPR/Cas system. The specification also describes systems for RNA-guided genome engineering and gene regulation in mammalian cells, including human cells.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Applicant: System Biosciences, LLCInventor: Fangting Wu
-
Patent number: 8835150Abstract: A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, and A199S/F227A/S287G/A328W/E441D all have enhanced catalytic efficiency for (?)-cocaine compared with wild-type BChE.Type: GrantFiled: February 14, 2013Date of Patent: September 16, 2014Assignee: University of Kentucky Research FoundationInventors: Chang-Guo Zhan, Hoon Cho, Hsin-Hsiung Tai
-
Publication number: 20140256798Abstract: The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.Type: ApplicationFiled: February 28, 2014Publication date: September 11, 2014Inventors: Mark J. Osborn, Jakub Tolar, Bruce Blazar, Daniel F. Voytas
-
Publication number: 20140256793Abstract: The present invention is directed to providing a medicament for treating or preventing a condition, disorder or disease associated with amyloid ?. Provided is a method for screening a medicament for treating or preventing a disease associated with amyloid ?, the method comprising: A) subjecting at least one of elements selected from the group consisting of 1) exosome; 2) neutral sphingomyelinase 2 (N-SMase2); and 3) sphingomyelin synthetic enzyme 2 (SMS2), and a candidate of the medicament in a condition in which they can interact with each other; and B) examining an influence by the candidate of the medicament to the element, wherein at least one of the elements is used as an index for determining as to whether or not the candidate is the medicament.Type: ApplicationFiled: October 12, 2012Publication date: September 11, 2014Inventors: Kohei Yuyama, Yasuyuki Igarashi, Susumu Mitsutake, Tetsuya Yoshida
-
Publication number: 20140248393Abstract: Disclosed are nucleotide sequences encoding thioesterase enzymes, methods for their production, their use in methods to form thioesters, and their use in methods of screening for other wild type bacteria capable of producing said thioesterase enzymes. Also disclosed are compositions comprising thioesters produced by the methods disclosed herein.Type: ApplicationFiled: September 26, 2011Publication date: September 4, 2014Inventors: Tarun Bhowmik, Jeff Broadbent, Dennis Welker, James Steele, Mateo Budinich
-
Patent number: 8822188Abstract: The present disclosure relates to the use of polypeptides having silicase activity for the modification or synthesis of silica, silicones and other silicium (IV) compounds. The present invention also relates to the use of polypeptides having silicase activity for the modification of glass, sand, asbestos, computer chips, glass wool, fiber glass, optical fibers and silicones, for the removal of sand from oil-sands, for the removal of asbestos, and for sandblasting.Type: GrantFiled: December 18, 2009Date of Patent: September 2, 2014Assignee: Novozymes A/SInventors: Janne Ejrnæs Toender, Martin Borchert
-
Patent number: 8821859Abstract: Articles and methods for the delivery of drugs and/or nucleic acids. Articles including a nanoparticle are provided that may be used for the delivery of a drug, a nucleic acid, or both, to a subject. The articles may be of polymeric material and may self-assemble.Type: GrantFiled: May 19, 2004Date of Patent: September 2, 2014Assignee: Agency for Science, Technology and ResearchInventors: Yi-Yan Yang, Yong Wang, Cherng-wen Tan, Jackie Y. Ying
-
Publication number: 20140242059Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.Type: ApplicationFiled: June 15, 2012Publication date: August 28, 2014Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATIONInventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
-
Publication number: 20140242036Abstract: The instant invention refers to a novel process for potentiating the production of substances with antifungal activity obtained from Ganoderma lucidum, using a technological device for the differential, qualitative and quantitative expression of proteins and other bioactive molecules, selected from the group consisting of polysaccharides, triterpenoids, fatty acids and ganoderic acids. The compositions containing said substances showed antifungal activity and mycelium growth and fungi ascospore germination inhibiting activity, amongst them Mycosphaerella fijiensis, primary pathogenic agent causing black Sigatoka disease in banana and plantain crop fields.Type: ApplicationFiled: June 18, 2013Publication date: August 28, 2014Inventors: JOHN JAIRO MIRA CASTILLO, PAOLA ANDREA ZAPATA OCAMPO, LUCíA ATEHORTÚA GARCÉS, LIUDA JOHANA SEPÚLVEDA ARANGO, DIEGO FERNANDO ROJAS VAHOS
-
Publication number: 20140242249Abstract: The invention relates to a recombinant DNA molecule encoding a polypeptide having phytase activity and increased temperature stability and increased proteolytic stability of the enzyme activity. The DNA sequence has been obtained by variation of the mature wild-type E. coli phytase sequence with defined amino acid positions being modified in comparison to the wild-type sequence or with the sequences having N- and/or C-terminal extensions, respectively. The invention further relates to a method for expressing the recombinant phytase as well as its use in the food and animal feed technologies.Type: ApplicationFiled: March 18, 2013Publication date: August 28, 2014Applicant: AB ENZYMES GMBHInventors: Khanh Q. Nguyen, Bruno Winter
-
Publication number: 20140234941Abstract: The present invention provides a novel phosphatidic acid phosphatase gene. The object of the present invention can be solved by providing a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5; a protein comprising the amino acid sequence set forth in SEQ ID NO: 2; and mutants thereof.Type: ApplicationFiled: July 27, 2012Publication date: August 21, 2014Applicant: SUNTORY HOLDINGS LIMITEDInventor: Misa Ochiai
-
Publication number: 20140234490Abstract: Provided herein are variants of Buttiauxella sp. phytases that may be used in industrial applications including methods for starch liquefaction, alcohol fermentations and for enhancing phosphate digestion in foods and animal feeds.Type: ApplicationFiled: January 22, 2014Publication date: August 21, 2014Applicant: Danisco US Inc.Inventors: Oliver Kensch, Klaus Schulze Pellengahr, Birgitta Leuthner, Jayarama K. Shetty, Michael Pepsin, Soren Dalsgaard, Mai Faurschou Isaksen
-
Publication number: 20140227246Abstract: The present invention relates to an anti-angiogenic composition, and more particularly, to a pharmaceutical anti-angiogenic composition including a microRNA-382 inhibitor. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis induced in a low oxygen environment. Therefore, the pharmaceutical composition of the present invention inhibits microRNA-382 and thus inhibits angiogenesis and cell proliferation, and is expected ultimately to be valuably used in the treatment of cancer.Type: ApplicationFiled: August 29, 2012Publication date: August 14, 2014Applicant: Kyungpook National University-Academic Cooprtation FoundationInventor: You Mie Lee
-
Publication number: 20140227245Abstract: The present invention relates to an angiogenic composition, and more particularly, to a pharmaceutical angiogenic composition including a microRNA-382 activator. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis. Therefore, provided in the present invention is the pharmaceutical angiogenic composition which includes the microRNA-382 activator, which is angiogenic and thus promotes cell proliferation, and can be valuably used in treating injuries, ischemic myocardial infarctions, or foot ischemia.Type: ApplicationFiled: August 29, 2012Publication date: August 14, 2014Inventor: You Mie Lee
-
Patent number: 8802413Abstract: This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.Type: GrantFiled: August 30, 2013Date of Patent: August 12, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Ronald T. Raines, Julie C. Mitchell, Thomas J. Rutkoski
-
Publication number: 20140223606Abstract: Compositions and methods comprising polynucleotides and polypeptides having meganuclease activity are provided. Further provided are nucleic acid constructs, yeast, plants, plant cells, explants, seeds and grain having the meganuclease sequences. Various methods of employing the meganuclease sequences are provided. Such methods include, for example, methods for producing a meganuclease with increased activity at a wide range of temperatures, methods for producing a yeast, plant, plant cell, explant or seed comprising a meganuclease with increased activity.Type: ApplicationFiled: May 3, 2013Publication date: August 7, 2014Applicants: PIONEER HI BRED INTERNATIONAL INC, E I DU PONT DE NEMOURS AND COMPANYInventors: E I DU PONT DE NEMOURS AND COMPANY, PIONEER HI BRED INTERNATIONAL INC
-
Publication number: 20140221233Abstract: The current invention relates to a method for identifying a subject at risk of developing an idiopathic inflammatory myopathy and/or diagnosing a subject suffering from an idiopathic inflammatory myopathy, preferably wherein said idiopathic inflammatory myopathy is Inclusion Body Myositis. The invention provides methods in diagnosis, use of specific antigens, and kits for use in studying the presence or absence of (auto)antibodies in samples derived from subjects.Type: ApplicationFiled: July 5, 2012Publication date: August 7, 2014Applicants: STICHTING KATHOLIEKE UNIVERSITEIT, STICHTING KATHOLIEKE UNIVERSITEITInventors: Gerardus Jozef Maria Pruijn, Wilhelmina Lamberta Leonarda Petronella Pluk, Basilius Gerardus Maria Van Engelen
-
Patent number: 8796004Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.Type: GrantFiled: February 21, 2013Date of Patent: August 5, 2014Assignee: CLS Therapeutics LimitedInventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
-
Publication number: 20140212885Abstract: The application provides a method of reducing the DNA content of a protein preparation or a culture broth from a filamentous fungal host cell using an endogenous filamentous fungal host DNase activity.Type: ApplicationFiled: September 20, 2012Publication date: July 31, 2014Applicant: Danisco US Inc.Inventors: Katherine M. Hoffmann, Douglas Ko, Michael Ward
-
Publication number: 20140215654Abstract: The present invention relates to variant thioesterases and their use in plants, e.g., to increase enzymatic activity and to promote increased production of mid-chain length fatty acids (e.g., 8 to 14 carbons) and at desired ratios. Further disclosed herein are methods of manufacturing renewable chemicals through the manufacture of novel triglyceride oils followed by chemical modification of the oils. Oils containing fatty acid chain lengths of C8, C10, C12 or C14 are also disclosed and are useful as feedstocks in the methods described herein.Type: ApplicationFiled: March 12, 2013Publication date: July 31, 2014Inventor: David Davis
-
Publication number: 20140205585Abstract: Methods of producing arylsulfatase A are described herein. The methods can include one or more steps of chromatography. Exemplary chromatographic steps include ion exchange chromatography, mixed mode chromatography, and hydrophobic interaction chromatography. Compositions containing and methods using arylsulfatase A produced by the methods described herein are also disclosed.Type: ApplicationFiled: July 9, 2012Publication date: July 24, 2014Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Ying Yang, Yong Wang
-
Publication number: 20140206755Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: February 3, 2014Publication date: July 24, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey
-
Patent number: 8778640Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: July 15, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8778641Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: July 15, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8778639Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: July 15, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Publication number: 20140194494Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: February 3, 2014Publication date: July 10, 2014Applicant: MODERNA THERAPEUTICS, INC.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Susan Whoriskey
-
Publication number: 20140193868Abstract: The present invention is in the field of biosynthesis of polyhydroxyalkanoates (PHA). The invention relates to a genetically engineered microorganism having at least one gene involved in the metabolism, preferably in the production, of polyhydroxyalkanoates (PHA). This microorganism is useful in commercial production of polyhydroxyalkanoates. The present invention further relates to a method for the production of polyhydroxyalkanoates (PHA).Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Inventors: Julia Sabirova, Peter Golyshin, Manuel Ferrer, Heinrich Lünsdorf, Wolf-Rainer Abraham, Kenneth Timmis
-
Publication number: 20140193388Abstract: The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of (genetically) modified phosphatases for treating or curing for example sepsis, inflammatory bowel disease or other inflammatory diseases, or renal failure. The invention further relates to a method for producing phosphatases.Type: ApplicationFiled: September 6, 2013Publication date: July 10, 2014Applicant: AM-PHARMA B.V.Inventors: MARKWIN PAUL VELDERS, LUIGI JOHANNES CORNELIUS JONK, WILLEM RAABEN, MARTY BERNARDUS FRANSISCUS WULFERINK
-
Publication number: 20140193878Abstract: A regulated deployment of a toxin gene for developmental programmed cell death in bacteria is described. M. xanthus is demonstrated to have a solitary mazF gene that lacks a cotranscribed antitoxin gene. Deletion of mazF results in elimination of the obligatory cell death during development causing dramatic reduction in spore formation. Surprisingly, MrpC functions as a MazF antitoxin and a mazF transcription activator. Transcription of mrpC and mazF is negatively regulated via MrpC phosphorylation by a Ser/Thr kinase cascade. Various methods of exploiting this novel pathway are described herein.Type: ApplicationFiled: July 1, 2013Publication date: July 10, 2014Applicant: University of Medicine and Dentistry of New JerseyInventors: Masayori Inouye, Hirofumi Nariya
-
Publication number: 20140193879Abstract: The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Applicant: Novozymes A/SInventors: Steffen Danielsen, Lars Kobberoee Skov, Ricardo Leite, Vincent Laize, M. Leonor Cancela Da Fonseca
-
Patent number: 8771985Abstract: Disclosed herein are methods and compositions for genome editing of a Rosa locus, using fusion proteins comprising a zinc-finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.Type: GrantFiled: April 25, 2011Date of Patent: July 8, 2014Assignees: Sangamo BioSciences, Inc., Sigma-Aldvich Co. LLCInventors: Xiaoxia Cui, Gregory Davis, Philip D. Gregory, Michael C. Holmes, Edward J. Weinstein
-
Patent number: 8772009Abstract: Methods and compositions for increasing nuclease activity by subjecting cells expressing the nuclease to hypothermic conditions to increase activity of the nucleases for genomic modifications.Type: GrantFiled: April 20, 2011Date of Patent: July 8, 2014Assignee: Sangamo BioSciences, Inc.Inventor: Yannick Doyon
-
Patent number: 8771994Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: July 8, 2014Assignee: Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8771993Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: July 8, 2014Assignees: Novozymes A/S, Novozymes Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8772008Abstract: Methods and compositions for increasing nuclease activity by subjecting cells expressing the nuclease to hypothermic conditions to increase activity of the nucleases for genomic modifications.Type: GrantFiled: May 18, 2010Date of Patent: July 8, 2014Assignee: Sangamo BioSciences, Inc.Inventor: Yannick Doyon